NVS
Price:
$154.62
Market Cap:
$292.91B
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Industry
Drug Manufacturers - General
IPO Date
1996-11-07
Stock Exchange
NYSE
Ticker
NVS
According to Novartis AG’s latest financial reports and current stock price. The company's current PE Ratio is 17.79. This represents a change of -20.41% compared to the average of 22.35 of the last 4 quarters.
The mean historical PE Ratio of Novartis AG over the last ten years is 20.20. The current 17.79 PE Ratio has changed 8.71% with respect to the historical average. Over the past ten years (40 quarters), NVS's PE Ratio was at its highest in in the December 2019 quarter at 47.43. The PE Ratio was at its lowest in in the December 2021 quarter at 3.02.
Average
20.20
Median
20.52
Minimum
8.22
Maximum
30.41
Discovering the peaks and valleys of Novartis AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 244.89%
Maximum Annual PE Ratio = 30.41
Minimum Annual Increase = -69.13%
Minimum Annual PE Ratio = 8.22
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 18.29 | 10.85% |
| 2024 | 16.50 | 16.21% |
| 2023 | 14.20 | -49.90% |
| 2022 | 28.34 | 244.89% |
| 2021 | 8.22 | -69.13% |
| 2020 | 26.62 | -12.46% |
| 2019 | 30.41 | 118.70% |
| 2018 | 13.90 | -38.91% |
| 2017 | 22.76 | -0.12% |
| 2016 | 22.79 | 120.41% |
The current PE Ratio of Novartis AG (NVS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
16.33
5-year avg
17.11
10-year avg
20.20
Novartis AG’s PE Ratio is less than AstraZeneca PLC (24.12), greater than GSK plc (15.96), less than Roche Holding AG (23.74), greater than Bristol-Myers Squibb Company (14.07), less than Sanofi (22.78), less than Merck & Co., Inc. (36.32), greater than Bayer AG (-22.47), greater than Gilead Sciences, Inc. (-50.20), less than Johnson & Johnson (29.84), less than AbbVie Inc. (69.46), less than Eli Lilly and Company (41.23), less than Pfizer Inc. (33.68),
| Company | PE Ratio | Market cap |
|---|---|---|
| 24.12 | $252.40B | |
| 15.96 | $103.32B | |
| 23.74 | $359.91B | |
| 14.07 | $130.45B | |
| 22.78 | $103.29B | |
| 36.32 | $319.32B | |
| -22.47 | $55.79B | |
| -50.20 | $162.05B | |
| 29.84 | $622.12B | |
| 69.46 | $435.62B | |
| 41.23 | $1.09T | |
| 33.68 | $145.27B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novartis AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novartis AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Novartis AG's PE Ratio?
How is the PE Ratio calculated for Novartis AG (NVS)?
What is the highest PE Ratio for Novartis AG (NVS)?
What is the 3-year average PE Ratio for Novartis AG (NVS)?
What is the 5-year average PE Ratio for Novartis AG (NVS)?
How does the current PE Ratio for Novartis AG (NVS) compare to its historical average?